This is a presentation by Xceleron CSO, Dr Graham Lappin, on the adoption of microdosing by the pharmaceutical industry and was given at the 2012 Annual AAPS Meeting in Chicago from 14-18 October at McCormick Place, Chicago. The presentation was part of a Thursday Morning Symposium on “Microdosing: Past Experience and Future Role in Translational Medicine” moderated by Malcolm Rowland of the University of Manchester. Read More »
This is a presentation given by Xceleron CSO, Dr Graham Lappin, at the DIA’s annual meeting, held June 24-28, 2012, in Philadelphia, PA. Read More »
Copy of presentation given by Xceleron’s CSO, Dr Graham Lappin, at the 2012 ASCPT meeting, held at the Gaylord National Hotel & Convention Center, National Harbor, Maryland from 12 – 17th March
This talk was given as part of a workshop called “Metabolites in Safety Testing: What Have Clinical Pharmacologists MIST” on the morning of Saturday 17th March and which included speakers from the FDA and Pfizer.
The presentation gives an overview on the methods available for the identification and quantitation of metabolites to satisfy the MIST guidance, as well as describing how Accelerator Mass Spectrometry can be used as part of an overall strategy in combination with other technologies to give quantifiable measurement of metabolites in all matrices. Case studies from industry are also given as examples.
This is a copy of a presentation given by Xceleron CSO, Professor Graham Lappin, at the 2nd Annual Biologics Symposium, Cambridge, UK
Professor Graham Lappin.
In this presentation, Graham explains the importance of mAb-target engagement and rate of target turnover in assessing whether or not an antiboby target is druggable and to determine the most appropriate dosing regimen.
Graham then describes ways in which AMS can be used to measure target production in both the presence of a suitable antibody and prior to antibody development. The talk also outlines a pre-competitive consortium that Xceleron are setting up with colleagues in the pharmaceutical industry to carry out proof of concept studies for this approach in the clinic.
A paper on a presentation by Dr Mark Seymour on the use of AMS as a frontline technique in bioanalytical detection has been published in the December 2011 issue of Bioanalysis. Read More »
Anti-Infective Microdose Study Aimed at MRSA. Microdosing studies were conducted to assess human PK, oral bioavailability, mass balance and distribution in skin blisters.
Celgene Absolute Bioavailability Data – ASCPT 2010 Poster Read More »
Hedgehog Pathway Inhibitor Bioavailability and Mass Balance – ASCO 2010 Posters Read More »
AMS and Tracer Studies at GSK – A ripple or a wavefront? Read More »
AstraZeneca Examples of using Micro Tracers – Exploratory Clinical Development 2010 Read More »
Microdosing studies: a consideration on analytical technology choice
"...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."
Find out how we can help you accelerate your drug-development program.